Clinicopathological Evaluation of Preoperative Chemotherapy Containing S-1 as a Treatment for Patients with Oral Squamous Cell Carcinoma during Waiting time for Surgery
Matsumiya, Y.; Imai, T.; Takeshita, A.; Meshii, N.; Katou, I.; Iwai, S.; Suematsu, M.; Omae, M.; Kanesaki, T.; Ota, Y.; Onishi, T.; Amino, K.; Sumi, T.; Niki, A.; Ueda, M.; Nakazawa, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(6): 1027-1031
2019
ISSN/ISBN: 0385-0684 PMID: 31273169 Document Number: 698389
In our department, patients with oral squamous cell carcinoma(OSCC)received preoperative chemotherapy containing S-1 to prevent the growth and dissemination of tumors during the waiting time before definitive surgery. We retrospectively evaluated the usefulness of this treatment. One hundred and five patients comprising stages T1(26), T2(64), T3(7), and T4(8 cases)were enrolled in this study from July 2001 to June 2013. In principle, patients were administered S-1(80mg/m / 2/day, days 1-14)and followed by a drug holiday(days 15-21), continuing until 1 week before surgery. The median administration period was 14 days(256 days). Ninety-eight patients underwent definitive surgery, but 7 patients who revealed clinical CR underwent only biopsy and showed histological CR. The histological responses of all patients were CR(24), PR(22), and NC(59), and the response rate was 43.8%. Almost all adverse effects were Grade 1 or 2, except 1 case of neutropenia(Grade 3)and 1 case of urticaria(Grade 3). The 5-year overall survival rates were 86.7% in all cases, 95.3% in CR/PR cases, and 79.7% in NC cases. Preoperative S-1 administration during the waiting time was a safe and very effective method and was considered beneficial for patients with OSCC.